126 related articles for article (PubMed ID: 30579799)
21. Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
Yao CH; Song JS; Chen CT; Yeh TK; Hung MS; Chang CC; Liu YW; Yuan MC; Hsieh CJ; Huang CY; Wang MH; Chiu CH; Hsieh TC; Wu SH; Hsiao WC; Chu KF; Tsai CH; Chao YS; Lee JC
J Med Chem; 2011 Jan; 54(1):166-78. PubMed ID: 21128592
[TBL] [Abstract][Full Text] [Related]
22. N-Indolylglycosides bearing modifications at the glucose C6-position as sodium-dependent glucose co-transporter 2 inhibitors.
Chu KF; Yao CH; Song JS; Chen CT; Yeh TK; Hsieh TC; Huang CY; Wang MH; Wu SH; Chang WE; Chao YS; Lee JC
Bioorg Med Chem; 2016 May; 24(10):2242-50. PubMed ID: 27075813
[TBL] [Abstract][Full Text] [Related]
23. 5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors.
Xu G; Du F; Kuo GH; Xu JZ; Liang Y; Demarest K; Gaul MD
Bioorg Med Chem Lett; 2020 Sep; 30(17):127387. PubMed ID: 32738984
[TBL] [Abstract][Full Text] [Related]
24. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Lapuerta P; Zambrowicz B; Strumph P; Sands A
Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors.
Kuo GH; Gaul MD; Liang Y; Xu JZ; Du F; Hornby P; Xu G; Qi J; Wallace N; Lee S; Grant E; Murray WV; Demarest K
Bioorg Med Chem Lett; 2018 Apr; 28(7):1182-1187. PubMed ID: 29523385
[TBL] [Abstract][Full Text] [Related]
26. Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes.
Goodwin NC; Ding ZM; Harrison BA; Strobel ED; Harris AL; Smith M; Thompson AY; Xiong W; Mseeh F; Bruce DJ; Diaz D; Gopinathan S; Li L; O'Neill E; Thiel M; Wilson AG; Carson KG; Powell DR; Rawlins DB
J Med Chem; 2017 Jan; 60(2):710-721. PubMed ID: 28045524
[TBL] [Abstract][Full Text] [Related]
27. The bark giving diabetes therapy some bite: the SGLT inhibitors.
Marshall SM
Diabetologia; 2018 Oct; 61(10):2075-2078. PubMed ID: 30132029
[No Abstract] [Full Text] [Related]
28. Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes.
Peacock SC; Lovshin JA; Cherney DZI
Anesth Analg; 2018 Feb; 126(2):699-704. PubMed ID: 28786838
[No Abstract] [Full Text] [Related]
29. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
[No Abstract] [Full Text] [Related]
30. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
Zhang Y; Nakano D; Guan Y; Hitomi H; Uemura A; Masaki T; Kobara H; Sugaya T; Nishiyama A
Kidney Int; 2018 Sep; 94(3):524-535. PubMed ID: 30045814
[TBL] [Abstract][Full Text] [Related]
31. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
[TBL] [Abstract][Full Text] [Related]
32. Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes.
Kong YK; Song KS; Jung ME; Kang M; Kim HJ; Kim MJ
Bioorg Med Chem Lett; 2022 Jan; 56():128466. PubMed ID: 34813882
[TBL] [Abstract][Full Text] [Related]
33. Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent.
Hasegawa M; Chino Y; Horiuchi N; Hachiuma K; Ishida M; Fukasawa Y; Nakai Y; Yamaguchi J
Xenobiotica; 2015; 45(12):1105-15. PubMed ID: 26489961
[TBL] [Abstract][Full Text] [Related]
34. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
[TBL] [Abstract][Full Text] [Related]
35. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
[TBL] [Abstract][Full Text] [Related]
36. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
[TBL] [Abstract][Full Text] [Related]
37. C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents.
Ding Y; Mao L; Xu D; Xie H; Yang L; Xu H; Geng W; Gao Y; Xia C; Zhang X; Meng Q; Wu D; Zhao J; Hu W
Bioorg Med Chem Lett; 2015 Jul; 25(14):2744-8. PubMed ID: 26026363
[TBL] [Abstract][Full Text] [Related]
38. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Danne T; Biester T; Kordonouri O
Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
[TBL] [Abstract][Full Text] [Related]
39. In the Search of Glycoside-Based Molecules as Antidiabetic Agents.
Pałasz A; Cież D; Trzewik B; Miszczak K; Tynor G; Bazan B
Top Curr Chem (Cham); 2019 Jun; 377(4):19. PubMed ID: 31165274
[TBL] [Abstract][Full Text] [Related]
40. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.
Song P; Onishi A; Koepsell H; Vallon V
Expert Opin Ther Targets; 2016 Sep; 20(9):1109-25. PubMed ID: 26998950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
